Our merger with Aceragen is a key development in our goal to help patients with rare diseases get more from life.
Learn MoreCompany completes preferred stock conversion, implements reverse stock split, and regains Nasdaq… Read more
EXTON, Pa. and DURHAM, N.C. , Nov. 14, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc.… Read more
Acquisition includes late-stage rare disease portfolio with anticipated 2023 clinical milestones… Read more